Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

Sponsor
Pyatigorsk City Clinical Hospital Number 1
Study ID
NCT07601867
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).

Key Dates

First listed
May 22, 2026
Start date
Jul 1, 2026
Status verified
May 2026
Primary completion
May 1, 2028
Completion
Jul 1, 2028

Study Design

Enrollment
72 participants (estimated)

Arms

  • Arm: Dapagliflozin Group
    Patients receiving dapagliflozin 10 mg once daily starting at 1 month after off-pump CABG

Primary Outcome Measure

Change in TAPSE/PASP Ratio [ Time Frame: 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin 10 mg/day) ]

Central Contacts

Find similar trials

Nationwide
Heart failure trialsCardiology trialsHeart disease trials

Related Studies